AR059589A2 - Proceso para la preparacion de sal de magnesio de trihidrato de s-omeprazol, sal de potasio de s-omeprazol intermediaria y proceso para prepararla - Google Patents

Proceso para la preparacion de sal de magnesio de trihidrato de s-omeprazol, sal de potasio de s-omeprazol intermediaria y proceso para prepararla

Info

Publication number
AR059589A2
AR059589A2 ARP070100714A ARP070100714A AR059589A2 AR 059589 A2 AR059589 A2 AR 059589A2 AR P070100714 A ARP070100714 A AR P070100714A AR P070100714 A ARP070100714 A AR P070100714A AR 059589 A2 AR059589 A2 AR 059589A2
Authority
AR
Argentina
Prior art keywords
omeprazol
omeprazole
salt
magnesium salt
trihydrate
Prior art date
Application number
ARP070100714A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059589(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR059589A2 publication Critical patent/AR059589A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)

Abstract

Un proceso para la preparacion de la sal de magnesio de trihidrato de S-omeprazol, que comprende los siguientes pasos: a) mezclar una sal de potasio de S-omeprazol con un disolvente orgánico; b) convertir la sal de potasio de S-omeprazol en una sal de magnesio correspondientes de S-omeprazol. tratando dicha sal de potasio con una fuente de magnesio; c) precipitar la sal de magnesio de S-omeprazol mediante el agregado de un no disolvente; d) aislar la sal de magnesio obtenida de S-omeprazol; e) tratar la sal de magnesio obtenida de S-omeprazol con agua; y f) aislar y secar la sal de magnesio de trihidrato de S-omeprazol obtenida de esa forma. También se revela la sal de potasio de S-omeprazol intermediaria y el proceso para prepararla.
ARP070100714A 1997-05-30 2007-02-20 Proceso para la preparacion de sal de magnesio de trihidrato de s-omeprazol, sal de potasio de s-omeprazol intermediaria y proceso para prepararla AR059589A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702065A SE510650C2 (sv) 1997-05-30 1997-05-30 Ny förening

Publications (1)

Publication Number Publication Date
AR059589A2 true AR059589A2 (es) 2008-04-16

Family

ID=20407186

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980102299A AR012717A1 (es) 1997-05-30 1998-05-18 Trihidrato de la sal de magnesio de s-omeprazol, proceso para su preparacion, composicion farmaceutica, y uso de dicho trihidrato para la fabricacion de medicamentos.
ARP070100714A AR059589A2 (es) 1997-05-30 2007-02-20 Proceso para la preparacion de sal de magnesio de trihidrato de s-omeprazol, sal de potasio de s-omeprazol intermediaria y proceso para prepararla

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980102299A AR012717A1 (es) 1997-05-30 1998-05-18 Trihidrato de la sal de magnesio de s-omeprazol, proceso para su preparacion, composicion farmaceutica, y uso de dicho trihidrato para la fabricacion de medicamentos.

Country Status (43)

Country Link
US (6) US6369085B1 (es)
EP (2) EP1273581B1 (es)
JP (2) JP4002303B2 (es)
KR (2) KR100540720B1 (es)
CN (1) CN1161351C (es)
AR (2) AR012717A1 (es)
AT (2) ATE291574T1 (es)
AU (1) AU722839B2 (es)
BR (1) BR9809509A (es)
CA (2) CA2290963C (es)
CY (1) CY2012029I1 (es)
CZ (1) CZ297585B6 (es)
DE (3) DE69814069T3 (es)
DK (2) DK0984957T3 (es)
DZ (1) DZ2495A1 (es)
EE (1) EE03875B1 (es)
EG (1) EG24291A (es)
ES (2) ES2195345T7 (es)
HR (1) HRP980263B1 (es)
HU (1) HU225987B1 (es)
ID (1) ID29306A (es)
IL (1) IL132947A0 (es)
IS (2) IS2142B (es)
LU (2) LU91871I2 (es)
MA (1) MA26500A1 (es)
ME (3) MEP18008A (es)
MY (2) MY127793A (es)
NO (3) NO317518B1 (es)
NZ (1) NZ500991A (es)
PL (1) PL193546B1 (es)
PT (2) PT984957E (es)
RS (2) RS50005B (es)
RU (1) RU2184115C2 (es)
SA (2) SA98190280B1 (es)
SE (1) SE510650C2 (es)
SI (2) SI1273581T1 (es)
SK (2) SK285137B6 (es)
TN (1) TNSN98074A1 (es)
TR (1) TR199902934T2 (es)
TW (1) TW538040B (es)
UA (1) UA60334C2 (es)
WO (1) WO1998054171A1 (es)
ZA (1) ZA984179B (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
JP4495465B2 (ja) * 2002-03-05 2010-07-07 アストラゼネカ・アクチエボラーグ オメプラゾール及びエソメプラゾールのアルキルアンモニウム塩
AU2003262375A1 (en) * 2002-04-22 2003-11-03 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
EP1515963B1 (en) 2002-06-27 2007-02-14 Dr. Reddy's Laboratories Ltd. A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
DE60311809T2 (de) * 2002-06-27 2007-11-22 Dr. Reddy's Laboratories Ltd. Verfahren zur herstellung optisch reiner oder optisch angereicherter sulfoxidverbindungen einschliesslich amorphen esomeprazols und dessen salze
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
WO2004020436A1 (en) * 2002-08-30 2004-03-11 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
EP1552833B1 (en) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
AU2003278406A1 (en) * 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Amorphous form of esomeprazole salts
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
US20060094762A1 (en) * 2003-01-07 2006-05-04 Yatendra Kumar Magnesium salt of imidazole derivative
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
US20070060556A1 (en) 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004260832A1 (en) * 2003-07-23 2005-02-10 Nycomed Gmbh Alkaline salts of proton pump inhibitors
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
AU2005216862A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
AU2005216863A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
CA2570795C (en) * 2004-06-24 2013-05-28 Astrazeneca Ab Process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
RU2007145207A (ru) * 2005-05-06 2009-06-20 Гленмарк Фармасьютикалз Лимитед (In) Стронциваемая соль эзомепразола, способ ее получения и содержащее ее фармацевтические композиции
US7563812B2 (en) 2005-06-15 2009-07-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
CA2626085C (en) * 2005-10-26 2011-12-06 Hanmi Pharm. Co., Ltd. S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US20100286208A1 (en) * 2006-06-21 2010-11-11 Bobba Venkata Siva Kumar Novel polymorph of esomeprazole potassium and process for its preparation
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EP1947099A1 (en) * 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
CA2889878A1 (en) * 2007-02-21 2008-08-28 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
US8492551B2 (en) * 2007-06-07 2013-07-23 Aurobindo Pharma. Ltd. Process for preparing an optically active proton pump inhibitor
FR2920428B1 (fr) 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
US8106210B2 (en) * 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
CN102014638A (zh) 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2240496A4 (en) * 2008-02-01 2011-05-11 Reddys Lab Ltd Dr PREPARATION OF MAGNESIUM OF ESOMEPRAZOLE AND ITS HYDRATES
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) * 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
CN101391993B (zh) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EP2438057A4 (en) * 2009-06-02 2013-12-25 Sun Pharmaceutical Ind Ltd PROCESS FOR PREPARING SULFOXIDE COMPOUNDS
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
WO2011012957A1 (en) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of esomeprazole magnesium dihydrate
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
WO2011071982A2 (en) 2009-12-08 2011-06-16 Codexis, Inc. Synthesis of prazole compounds
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (fr) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
CN102241668B (zh) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 S-奥美拉唑盐
HUE037616T2 (hu) 2010-12-08 2018-09-28 Codexis Inc Biokatalizátorok és eljárások armodafinil szintéziséhez
CN102757421A (zh) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 埃索美拉唑的纯化方法
CN104844577A (zh) * 2011-07-31 2015-08-19 连云港润众制药有限公司 埃索美拉唑镁的晶型
CN102924435B (zh) * 2011-11-25 2014-06-25 成都自豪药业有限公司 S-奥美拉唑镁盐的晶型及其制备方法
WO2013088272A1 (en) * 2011-12-14 2013-06-20 Wockhardt Limited Pharmaceutical composition comprising esomeprazole magnesium dihydrate
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
CN104250243B (zh) * 2013-06-27 2016-12-28 四川国为制药有限公司 一种埃索美拉唑镁二水合物a晶型的制备方法
CN103570686B (zh) * 2013-10-14 2015-04-01 哈药集团技术中心 一种埃索美拉唑钠的合成及精制工艺
CN104725357A (zh) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 一种埃索美拉唑镁二水合物晶型b的制备方法
FR3018812A1 (fr) * 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
CN104447699A (zh) * 2014-12-10 2015-03-25 哈药集团技术中心 一种埃索美拉唑镁三水合物的制备方法
CN105111188B (zh) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 一种埃索美拉唑镁三水合物晶型的制备方法
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106397402B (zh) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 一种埃索美拉唑镁晶型化合物及其制备方法
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
WO2020040233A1 (ja) * 2018-08-21 2020-02-27 東和薬品株式会社 化合物の特定形状の結晶及びその製造方法
WO2020040438A1 (ko) 2018-08-23 2020-02-27 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification
CN119320380B (zh) * 2024-10-14 2025-11-25 山东益康药业股份有限公司 奥美拉唑与2,6-二羟基苯甲酸的共晶物及其用途
CN119320381B (zh) * 2024-10-14 2025-12-12 山东益康药业股份有限公司 奥美拉唑与3,5-二硝基苯甲酸的共晶物及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US5244891A (en) * 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
FR2719045B1 (fr) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Procédé de préparation d'acide L-aspartique à partir d'aspartate d'ammonium.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
CZ289804B6 (cs) 1994-07-08 2002-04-17 Astrazeneca Ab Multijednotková tabletovaná dávková forma I
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
FI972035A7 (fi) * 1994-11-14 1997-07-11 Daiichi Seiyaku Co Hydraatti lääketieteellistä käyttöä varten
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (zh) 1995-05-25 1999-03-10 常州市第四制药厂 奥美拉唑盐水合物及其制备方法
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Also Published As

Publication number Publication date
LU92017I2 (fr) 2012-08-06
NO2011010I1 (no) 2011-06-20
CZ297585B6 (cs) 2007-01-10
HU0001849D0 (es) 2002-05-29
NZ500991A (en) 2001-05-25
US20050075369A1 (en) 2005-04-07
TR199902934T2 (xx) 2000-04-21
IS8368A (is) 2006-03-22
MEP24908A (en) 2010-10-10
HRP980263A2 (en) 1999-02-28
RS50005B (sr) 2008-09-29
US6369085B1 (en) 2002-04-09
SA05260296B1 (ar) 2008-04-16
RS50067B (sr) 2009-01-22
SI0984957T1 (en) 2003-10-31
KR100527804B1 (ko) 2005-11-15
HRP980263B1 (en) 2002-02-28
EP1273581A1 (en) 2003-01-08
ES2195345T3 (es) 2003-12-01
DE69814069T2 (de) 2004-04-01
KR20010013126A (ko) 2001-02-26
US8076361B2 (en) 2011-12-13
PT1273581E (pt) 2005-06-30
EP0984957A1 (en) 2000-03-15
US20020198239A1 (en) 2002-12-26
JP2007161734A (ja) 2007-06-28
EP0984957B3 (en) 2013-09-18
YU60999A (sh) 2002-03-18
TW538040B (en) 2003-06-21
CA2290963C (en) 2006-03-28
SE9702065L (sv) 1998-12-01
US8466175B2 (en) 2013-06-18
US6677455B2 (en) 2004-01-13
PL193546B1 (pl) 2007-02-28
DE122012000017I1 (de) 2012-08-16
MA26500A1 (fr) 2004-12-20
HUP0001849A2 (hu) 2002-05-29
CN1161351C (zh) 2004-08-11
DE69829511D1 (de) 2005-04-28
DK1273581T3 (da) 2005-06-06
CA2290963A1 (en) 1998-12-03
RU2184115C2 (ru) 2002-06-27
DZ2495A1 (fr) 2003-01-25
DE69829511T2 (de) 2006-02-16
PT984957E (pt) 2003-07-31
IS2774B (is) 2012-03-15
LU91871I2 (fr) 2011-11-21
NO2012011I1 (no) 2012-06-18
CA2521391A1 (en) 1998-12-03
SK284837B6 (sk) 2005-12-01
KR100540720B1 (ko) 2006-01-12
ATE239011T1 (de) 2003-05-15
HK1025962A1 (en) 2000-12-01
IS5272A (is) 1999-11-25
ME00198B (me) 2011-02-10
CY2012029I2 (el) 2015-08-05
BR9809509A (pt) 2000-06-20
WO1998054171A1 (en) 1998-12-03
EP0984957B1 (en) 2003-05-02
NO995852D0 (no) 1999-11-29
EE03875B1 (et) 2002-10-15
IS2142B (is) 2006-09-15
ES2195345T7 (es) 2014-01-15
SA98190280B1 (ar) 2006-07-04
MEP18008A (en) 2010-10-10
SK162599A3 (en) 2000-06-12
ID29306A (id) 2001-08-16
NO317518B1 (no) 2004-11-08
TNSN98074A1 (fr) 2005-03-15
DK0984957T3 (da) 2003-06-30
HU225987B1 (en) 2008-02-28
CY2012029I1 (el) 2015-08-05
AU7793598A (en) 1998-12-30
ATE291574T1 (de) 2005-04-15
CA2521391C (en) 2009-09-29
NO995852L (no) 2000-01-31
EG24291A (en) 2009-01-08
CN1258295A (zh) 2000-06-28
US20110130570A1 (en) 2011-06-02
EE9900550A (et) 2000-06-15
ES2236407T3 (es) 2005-07-16
DE69814069T3 (de) 2014-03-27
AU722839B2 (en) 2000-08-10
US20120252847A1 (en) 2012-10-04
DE69814069D1 (de) 2003-06-05
JP2002501529A (ja) 2002-01-15
RS20070459A (sr) 2008-06-05
MY120745A (en) 2005-11-30
HUP0001849A3 (en) 2003-02-28
MY127793A (en) 2006-12-29
US20080255363A1 (en) 2008-10-16
PL337180A1 (en) 2000-08-14
US7411070B2 (en) 2008-08-12
AR012717A1 (es) 2000-11-08
HK1051681A1 (en) 2003-08-15
EP1273581B1 (en) 2005-03-23
US7745466B2 (en) 2010-06-29
JP4002303B2 (ja) 2007-10-31
SI1273581T1 (es) 2005-08-31
SK285137B6 (sk) 2006-07-07
KR20050042827A (ko) 2005-05-10
UA60334C2 (uk) 2003-10-15
WO1998054171A8 (en) 1999-12-23
SE510650C2 (sv) 1999-06-14
ZA984179B (en) 1998-11-30
SE9702065D0 (sv) 1997-05-30
IL132947A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
ES2542853T3 (es) Método para tratar miastenia grave
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
CO4520208A1 (es) Estabilizador para perforacion direccional
ES2121689B1 (es) Aceleradores para hormigon.
ES2184127T3 (es) Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
ES2134316T3 (es) Composicion inhibitoria de la corrosion para hormigon reforzado y metodo para su aplicacion.
ES2034176T3 (es) Metodo para la remocion de geles de polimeros de un yacimiento de petroleo.
AR028162A1 (es) Disponibilidad controlada de compuestos de formulacion, composiciones y metodos para el lavado que utilizan los mismos.
CR9490A (es) Composiciones de ciclopropeno
ES2170759T3 (es) Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos.
CO5050408A1 (es) Proceso para purificar caprolactama con la ayuda de un solvente organico de caprolactama
MX9204288A (es) Procedimiento para recuperar los residuos de polivinilbutiral mediante reciclado.
BR0114797B1 (pt) método para a remoção de água de um composto de organoborano úmido.
ES2107826T3 (es) Procedimiento de fabricacion de una pelicula biodegradable, hidrofoba y transparente y pelicula asi obtenida.
BR9801507A (pt) Despolimerização de poliamidas.
MX9207350A (es) Agentes de mantenimiento para superficies duras.
MX9102117A (es) Metodo para el tratamiento de nematodos en terreno, empleando furfural.
WO2001088532A3 (en) Improved assay techniques using nematode worms
ES2100051T3 (es) Sintesis de bloques dimeros y su uso en el ensamblaje de oligonucleotidos.
PE37199A1 (es) Agente reductor para alquilacion reductiva de antibioticos glicopeptidos
AR026778A1 (es) Tratamiento de agua
EA200100130A1 (ru) Способ выделения гидроксиметилтиобутановой кислоты
AR011572A1 (es) Un compuesto derivado de la imino-aza-antraciclinona, su uso, un procedimiento para prepararlo, una composicion farmaceutica que lo comprendey un metodo para tratar dolencias de seres humanos o animales derivadas de alguna enfermedad amiloidea, o susceptibles de ella.
ES519400A0 (es) Dispositivo para el tratamiento de agua residual por medio de fermentacion anaerobica.
ES2148874T3 (es) Composicion antioxidante y metodo para su produccion.

Legal Events

Date Code Title Description
FG Grant, registration